Preclinical studies have demonstrated that PH-762 is rapidly absorbed by cells, effectively silencing PD-1 mRNA and protein in lymphocytes within the tumor microenvironment. Moreover, intratumoral injection of mPH-762 in murine tumor models has significantly inhibited tumor growth while being well-tolerated. Studies in non-human primates have also indicated that PH-762 is safe and does not induce cytokine release syndrome. These findings support the ongoing clinical trial evaluating PH-762’s safety and efficacy as a neoadjuvant therapy for various cancers.
PHIO Pharmaceuticals Reports Positive Preclinical Data for Lead Clinical Product Candidate, PH-762
